

Wei-Lien Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1825275/publications.pdf>

Version: 2024-02-01

168
papers

6,272
citations

101384

36
h-index

85405

71
g-index

169
all docs

169
docs citations

169
times ranked

8614
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. <i>European Urology Oncology</i> , 2023, 6, 228-232.	2.6	11
2	Gastrointestinal stromal tumors (GISTs) arising in uncommon locations: clinicopathologic features and risk assessment of esophageal, colonic, and appendiceal GISTs. <i>Modern Pathology</i> , 2022, 35, 554-563.	2.9	9
3	Utility of SOX11 for the diagnosis of solid pseudopapillary neoplasm of the pancreas on cytological preparations. <i>Cytopathology</i> , 2022, 33, 216-221.	0.4	4
4	Global assessment of IRF8 as a novel cancer biomarker. <i>Human Pathology</i> , 2022, 122, 1-10.	1.1	6
5	Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. <i>Human Pathology</i> , 2022, 121, 73-80.	1.1	18
6	Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component. <i>Modern Pathology</i> , 2022, 35, 922-928.	2.9	4
7	Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. <i>International Journal of Cancer</i> , 2022, 150, 2012-2024.	2.3	8
8	SATB2 Expression in Undifferentiated Pleomorphic Sarcomas of Bone. <i>American Journal of Clinical Pathology</i> , 2022, , .	0.4	1
9	Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. <i>Oncotarget</i> , 2022, 13, 521-533.	0.8	4
10	The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. <i>Molecular Cell</i> , 2022, 82, 1737-1750.e8.	4.5	11
11	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. <i>Nature Communications</i> , 2022, 13, 1797.	5.8	23
12	Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall. <i>Human Pathology</i> , 2022, 125, 35-47.	1.1	5
13	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. <i>British Journal of Cancer</i> , 2022, 127, 569-576.	2.9	8
14	Pigmented PRRX1::NCOA1-rearranged fibroblastic tumor: A rare morphologic variant of an emerging mesenchymal tumor. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 802-807.	0.7	2
15	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	14
16	A phase II multi-arm study to test the efficacy of oleclumab and durvalumab in specific sarcoma subtypes. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS11594-TPS11594.	0.8	3
17	A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC). <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1128-TPS1128.	0.8	1
18	Randomized phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS): Survival results after 2 years of follow-up and intratumoral B-cell receptor (BCR) correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA11501-LBA11501.	0.8	11

#	ARTICLE	IF	CITATIONS
19	LMNA&NTRK1 rearranged mesenchymal tumor (lipofibromatosis&like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 290-294.	0.7	9
20	Radiation&associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation<sup></sup>. <i>Histopathology</i> , 2021, 78, 321-326.	1.6	18
21	RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors. <i>Modern Pathology</i> , 2021, 34, 951-960.	2.9	14
22	Primary superficial synovial sarcoma: clinical and histopathological characteristics in eight cases with molecular confirmation. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 263-268.	0.7	0
23	Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma. <i>Human Pathology</i> , 2021, 108, 42-50.	1.1	22
24	INSM1 Expression in Angiosarcoma. <i>American Journal of Clinical Pathology</i> , 2021, 155, 575-580.	0.4	6
25	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. <i>Oncologist</i> , 2021, 26, 250-260.	1.9	9
26	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. <i>Cell Reports</i> , 2021, 34, 108678.	2.9	33
27	Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 871-882.	1.1	12
28	Chondrosarcoma. <i>Journal of the American Academy of Orthopaedic Surgeons, The</i> , 2021, 29, 553-562.	1.1	32
29	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. <i>Cancer</i> , 2021, 127, 2666-2673.	2.0	15
30	Dermatofibrosarcoma protuberans in pregnancy: a case series and review of the literature. <i>International Journal of Dermatology</i> , 2021, 60, 1114-1119.	0.5	7
31	Combined VEGFR and MAPK pathway inhibition in angiosarcoma. <i>Scientific Reports</i> , 2021, 11, 9362.	1.6	14
32	A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. <i>British Journal of Cancer</i> , 2021, 125, 1333-1340.	2.9	22
33	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. <i>Acta Neuropathologica</i> , 2021, 142, 565-590.	3.9	12
34	Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. <i>Cell Reports</i> , 2021, 36, 109410.	2.9	17
35	Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 842-850.	1.2	0
36	Osteofibrous dysplasia and adamantinoma: A summary of diagnostic challenges and surgical techniques. <i>Surgical Oncology</i> , 2021, 38, 101626.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Surgical Management of Primary Skull Base Osteosarcomas: Impact of Margin Status and Patterns of Relapse. <i>Neurosurgery</i> , 2020, 86, E23-E32.	0.6	9
38	Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. <i>Modern Pathology</i> , 2020, 33, 496-513.	2.9	19
39	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. <i>Cell Reports</i> , 2020, 33, 108293.	2.9	39
40	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. <i>Sarcoma</i> , 2020, 2020, 1-6.	0.7	16
41	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
42	Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. <i>Clinical Sarcoma Research</i> , 2020, 10, 14.	2.3	11
43	Proliferative fasciitis mimicking sarcoma in the breast. <i>Breast Journal</i> , 2020, 26, 2072-2074.	0.4	1
44	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	1.7	20
45	Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. <i>Breast Cancer Research</i> , 2020, 22, 69.	2.2	45
46	<i>Soft Tissue.</i> , 2020, , 229-283.		0
47	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	5.8	143
48	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	13.7	1,158
49	Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. <i>Cancer</i> , 2020, 126, 3265-3273.	2.0	18
50	The immune microenvironment of uterine adenosarcomas. <i>Clinical Sarcoma Research</i> , 2020, 10, 5.	2.3	4
51	Correlative Analyses of the SARCO28 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 1258-1266.	3.2	115
52	Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).. <i>Journal of Clinical Oncology</i> , 2020, 38, 11505-11505.	0.8	28
53	A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11509-11509.	0.8	13
54	Maneuvering the Management of a Rare Case of Primary Undifferentiated Cardiac Sarcoma. <i>American Journal of Case Reports</i> , 2020, 21, e918878.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer.. Journal of Clinical Oncology, 2020, 38, 5049-5049.	0.8	0
56	Identifying functional loss of ATM gene in patients with advanced cancer.. Journal of Clinical Oncology, 2020, 38, 3629-3629.	0.8	1
57	AXL Inhibition Enhances MEK Inhibitor Sensitivity in Malignant Peripheral Nerve Sheath Tumors. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, 511-525.	0.2	0
58	Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. Journal of the American Academy of Dermatology, 2019, 80, 189-207.e11.	0.6	16
59	PAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation. Modern Pathology, 2019, 32, 154-156.	2.9	10
60	The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. Journal of Surgical Oncology, 2019, 120, 382-388.	0.8	5
61	Disseminated anaplastic pleomorphic xanthoastrocytoma with posttreatment fat necrosis during combined BRAF and MEK inhibitors therapy. Pediatric Blood and Cancer, 2019, 66, e27974.	0.8	2
62	Comparison of published risk models for prediction of outcome in patients with extracranial solitary fibrous tumour. Histopathology, 2019, 75, 723-737.	1.6	40
63	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers, 2019, 11, 677.	1.7	20
64	Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. BMJ Case Reports, 2019, 12, e218839.	0.2	3
65	Prognostic significance of human telomerase reverse transcriptase promoter region mutations C228T and C250T for overall survival in spinal chordomas. Neuro-Oncology, 2019, 21, 1005-1015.	0.6	15
66	Long-Term Outcomes for Patients With Desmoid Fibromatosis Treated With Radiation Therapy: A 10-Year Update and Re-evaluation of the Role of Radiation Therapy for Younger Patients. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1167-1174.	0.4	26
67	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. Journal of Investigative Dermatology, 2019, 139, 728-731.	0.3	8
68	Calcified leiomyoma of the deltoid: pathophysiology and imaging review. Skeletal Radiology, 2019, 48, 625-628.	1.2	3
69	Prognostication in Mesenchymal Tumors. Surgical Pathology Clinics, 2019, 12, 217-225.	0.7	0
70	A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 385-385.	0.8	3
71	Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma (UBC).. Journal of Clinical Oncology, 2019, 37, 4521-4521.	0.8	0
72	Salvage Surgery for Recurrent Retroperitoneal Well-Differentiated Liposarcoma: Early Reoperation may not Provide Benefit. Annals of Surgical Oncology, 2018, 25, 2193-2200.	0.7	34

#	ARTICLE	IF	CITATIONS
73	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. <i>Cancer Cytopathology</i> , 2018, 126, 342-352.	1.4	102
74	Summary of expression of SPARC protein in cutaneous vascular neoplasms and mimickers. <i>Annals of Diagnostic Pathology</i> , 2018, 34, 151-154.	0.6	3
75	Genomic profiling of dedifferentiated liposarcoma compared to matched well-differentiated liposarcoma reveals higher genomic complexity and a common origin. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002386.	0.5	45
76	Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 563-580.	0.7	22
77	Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. <i>Cancer Cytopathology</i> , 2018, 126, 406-413.	1.4	33
78	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
79	Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. <i>Journal of Surgical Oncology</i> , 2018, 117, 879-885.	0.8	7
80	Superficial Solitary Fibrous Tumor. <i>American Journal of Surgical Pathology</i> , 2018, 42, 778-785.	2.1	36
81	The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018, 117, 1799-1805.	0.8	7
82	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1315-1323.	1.9	13
83	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018, 20, 37.	1.8	27
84	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	2.1	46
85	Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. <i>Clinical Cancer Research</i> , 2018, 24, 521-531.	3.2	64
86	Imaging of liposarcomas for clinicians: Characteristic features and differential considerations. <i>Journal of Surgical Oncology</i> , 2018, 117, 1195-1203.	0.8	9
87	Concomitant organ resection does not improve outcomes in primary retroperitoneal well-differentiated liposarcoma: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018, 117, 1188-1194.	0.8	31
88	Primary chondroosseous melanoma (chondrosarcomatous and osteosarcomatous melanoma). <i>Journal of Cutaneous Pathology</i> , 2018, 45, 146-150.	0.7	12
89	Long-Term Survival According to Histology and Radiologic Response to Preoperative Chemotherapy in 126 Patients Undergoing Resection of Non-GIST Sarcoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 107-116.	0.7	15
90	Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. <i>Histopathology</i> , 2018, 72, 239-247.	1.6	19

#	ARTICLE	IF	CITATIONS
91	The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1297-1310.	1.2	16
92	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018, 18, 913.	1.1	69
93	Bone and Soft Tissue Tumors About the Foot and Ankle. <i>Radiologic Clinics of North America</i> , 2018, 56, 917-934.	0.9	13
94	Nuclear β -catenin localization and mutation of the CTNNB1 gene: a context-dependent association. <i>Modern Pathology</i> , 2018, 31, 1553-1559.	2.9	90
95	The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. <i>Cancer Cell</i> , 2018, 33, 1128-1141.e7.	7.7	169
96	Tumor thrombus in the large veins draining primary pelvic osteosarcoma on cross sectional imaging. <i>European Journal of Radiology</i> , 2018, 105, 49-55.	1.2	13
97	<i>TERT</i> promoter mutations in solitary fibrous tumour. <i>Histopathology</i> , 2018, 73, 843-851.	1.6	47
98	Ganglioglioma in children and young adults: single institution experience and review of the literature. <i>Journal of Neuro-Oncology</i> , 2018, 139, 739-747.	1.4	26
99	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. <i>Oncotarget</i> , 2018, 9, 1602-1616.	0.8	15
100	Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. <i>Oncotarget</i> , 2018, 9, 19891-19899.	0.8	28
101	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10520-10520.	0.8	0
102	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11522-11522.	0.8	0
103	Stage at presentation to determine associations between histologic parameters of primary tumor and disease specific survival (DSS) in anorectal melanoma (AM).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21622-e21622.	0.8	0
104	Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. <i>European Journal of Cancer</i> , 2017, 76, 76-83.	1.3	32
105	EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. <i>Modern Pathology</i> , 2017, 30, 1312-1320.	2.9	69
106	Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 692-697.	0.7	5
107	Periosteal mesenchymal chondrosarcoma of the tibia with multifocal bone metastases: a case report. <i>Skeletal Radiology</i> , 2017, 46, 995-1000.	1.2	4
108	Undifferentiated round-cell (Ewing-like) sarcoma: not always so-round nor Ewing-like. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 371-372.	1.4	10

#	ARTICLE	IF	CITATIONS
109	The role of phosphorylated signal transducer and activator of transcription 3 (<scp>pSTAT</scp>3) in peripheral nerve sheath tumours. <i>Histopathology</i> , 2017, 70, 946-953.	1.6	8
110	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. <i>Scientific Reports</i> , 2017, 7, 9519.	1.6	15
111	Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. <i>Modern Pathology</i> , 2017, 30, 1433-1442.	2.9	261
112	USP6 activation in nodular fasciitis by promoter-swapping gene fusions. <i>Modern Pathology</i> , 2017, 30, 1577-1588.	2.9	79
113	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	1.9	20
114	Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. <i>Cancer Biology and Therapy</i> , 2017, 18, 816-826.	1.5	19
115	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Oncolmmunology</i> , 2017, 6, e1321187.	2.1	45
116	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , 2017, 7, 11.	2.3	61
117	Molecular profiling of sarcomas: new vistas for precision medicine. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 243-255.	1.4	9
118	Calcified synovial metastasis in the knee from renal cell carcinoma: a case report. <i>Skeletal Radiology</i> , 2017, 46, 123-127.	1.2	9
119	Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11019-11019.	0.8	0
120	Non-Radiographic Risk Factors Differentiating Atypical Lipomatous Tumors from Lipomas. <i>Frontiers in Oncology</i> , 2016, 6, 197.	1.3	15
121	Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. <i>JAMA Surgery</i> , 2016, 151, 347.	2.2	40
122	Cutaneous nodular fasciitis with genetic analysis: a case series. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1143-1149.	0.7	19
123	Uterine Adenosarcoma: a Review. <i>Current Oncology Reports</i> , 2016, 18, 68.	1.8	62
124	Sarcoma Brain Metastases: 28ÂYears of Experience at a Single Institution. <i>Annals of Surgical Oncology</i> , 2016, 23, 962-967.	0.7	15
125	Spinal column chordoma: prognostic significance of clinical variables andT (brachyury) gene SNP rs2305089 for local recurrence and overall survival. <i>Neuro-Oncology</i> , 2016, 19, now156.	0.6	27
126	Myxofibrosarcoma. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 775-788.	0.6	67

#	ARTICLE	IF	CITATIONS
127	Modeling synovial sarcoma metastasis in the mouse: PI3 α 2-lipid signaling and inflammation. <i>Journal of Experimental Medicine</i> , 2016, 213, 2989-3005.	4.2	29
128	How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 787-792.	2.3	4
129	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. <i>Modern Pathology</i> , 2016, 29, 582-590.	2.9	164
130	Cardiovascular involvement by osteosarcoma: an analysis of 20 patients. <i>Pediatric Radiology</i> , 2016, 46, 21-33.	1.1	27
131	Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2220-2228.	0.7	24
132	MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours. <i>British Journal of Radiology</i> , 2016, 89, 20150308.	1.0	17
133	Clinical characteristics and treatment outcome in a large multicenter observational cohort of pdgfra exon 18 mutated gastrointestinal stromal tumor (GIST) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11011-11011.	0.8	1
134	Expression and clinical correlations of PRAME in sarcoma subtypes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11067-11067.	0.8	10
135	Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11069-11069.	0.8	0
136	Treatment Challenges with Benign Bone Tumors of the Orbit. <i>Ocular Oncology and Pathology</i> , 2015, 1, 111-120.	0.5	4
137	Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. <i>Clinical Sarcoma Research</i> , 2015, 5, 22.	2.3	33
138	AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. <i>BMC Cancer</i> , 2015, 15, 901.	1.1	22
139	Molecular characterization of epithelioid haemangioendotheliomas identifies novel <i>WWTR</i> α 1 β 1 fusion variants. <i>Histopathology</i> , 2015, 67, 699-708.	1.6	67
140	Metastatic Atypical Fibroxanthoma. <i>American Journal of Dermatopathology</i> , 2015, 37, 455-461.	0.3	40
141	Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. <i>Human Pathology</i> , 2015, 46, 1015-1026.	1.1	18
142	Prognostic Factors and Patterns of Relapse in Ewing Sarcoma Patients Treated With Chemotherapy and R0 Resection. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 349-357.	0.4	23
143	BCOR α CCNB3 fusions are frequent in undifferentiated sarcomas of male children. <i>Modern Pathology</i> , 2015, 28, 575-586.	2.9	122
144	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.3	138

#	ARTICLE	IF	CITATIONS
145	Molecular Testing in Cutaneous Mesenchymal Tumors. <i>Molecular Pathology Library</i> , 2015, , 37-54.	0.1	0
146	Clinical Characteristics and Treatment Outcomes of Clear Cell Chondrosarcomas: MD Anderson Cancer Center Series.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10531-10531.	0.8	0
147	A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9039-9039.	0.8	0
148	Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10550-10550.	0.8	0
149	A Single Case of Rosai-ÂœDorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine. <i>Frontiers in Oncology</i> , 2014, 4, 297.	1.3	10
150	ERG and FLI1 protein expression in epithelioid sarcoma. <i>Modern Pathology</i> , 2014, 27, 496-501.	2.9	81
151	Soft tissue Langerhans cell histiocytosis with secondary bone involvement in extremities: evolution of lesions in two patients. <i>Skeletal Radiology</i> , 2013, 42, 1301-1309.	1.2	11
152	Retroperitoneal undifferentiated pleomorphic sarcoma having microsatellite instability associated with Muir-ÂœTorre syndrome: case report and review of literature. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 730-733.	0.7	10
153	FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma. <i>Modern Pathology</i> , 2012, 25, 846-853.	2.9	72
154	Expression of ERG, an Ets family transcription factor, identifies ERG-rearranged Ewing sarcoma. <i>Modern Pathology</i> , 2012, 25, 1378-1383.	2.9	111
155	CTNNB1 Genotyping and APC Screening in Pediatric Desmoid Tumors: A Proposed Algorithm. <i>Pediatric and Developmental Pathology</i> , 2012, 15, 361-367.	0.5	40
156	Enchondroma with secondary aneurysmal bone cyst. <i>Skeletal Radiology</i> , 2012, 41, 1475-1478.	1.2	3
157	Painful left shoulder. <i>Skeletal Radiology</i> , 2012, 41, 1489-1490.	1.2	0
158	Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. <i>Clinical Sarcoma Research</i> , 2012, 2, 25.	2.3	22
159	Sarcoma metastases to the skin. <i>Cancer</i> , 2012, 118, 2900-2904.	2.0	34
160	Epithelioid Inflammatory Myofibroblastic Sarcoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 135-144.	2.1	309
161	The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. <i>Histopathology</i> , 2011, 59, 556-561.	1.6	23
162	'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis. <i>Histopathology</i> , 2011, 59, 336-340.	1.6	36

#	ARTICLE	IF	CITATIONS
163	Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 15-24.	1.1	59
164	COL1A1:PDGFB Chimeric Transcripts Are Not Present in Indeterminate Fibrohistiocytic Lesions of the Skin. <i>American Journal of Dermatopathology</i> , 2010, 32, 149-153.	0.3	14
165	Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). <i>Modern Pathology</i> , 2009, 22, 1201-1209.	2.9	198
166	Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors: A Series of 5 Cases With Molecular Analysis Cutaneous and Subcutaneous Metastases of Gastrointestinal Stromal Tumors : A Series of 5 Cases with Molecular Analysis.. <i>American Journal of Dermatopathology</i> , 2009, 31, 297-300.	0.3	20
167	Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome. <i>Annals of Surgery</i> , 2009, 249, 1014-1022.	2.1	254
168	Fluorescence in situ hybridization is a useful ancillary diagnostic tool for extraskeletal myxoid chondrosarcoma. <i>Modern Pathology</i> , 2008, 21, 1303-1310.	2.9	44